Antiretroviral therapy and resistance to antiretroviral drugs.
Slightly more than a decade after the discovery of HIV as the causative agent of AIDS, effective therapies against this virus have become available. Because of a large degree of cross-resistance among antiretroviral agents in the same class (nRTIs, NNRTIs, or PIs), once a therapy has failed virologically, future therapeutic options with currently available drugs are limited, however. Poor tolerability and toxicity may also compromise the long-term prospects of antiretroviral therapy. Nevertheless, benefits of antiretroviral therapy far outweigh the downsides and efforts to scale up responsible use of antiretroviral agents in developing countries are a priority in the fight against HIV/AIDS. This paper presents an overview of antiretroviral therapy and resistance to antiretroviral drugs.
Lange
Joep M A
JM
International Antiviral Therapy Evaluation Centre (IATEC), Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
van Leeuwen
Remko
R
D016915:AIDS Vaccines; D019380:Anti-HIV Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D003906:Developing Countries; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D006292:Health Priorities; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D018579:Patient Selection; D011322:Primary Prevention / Q000379:methods; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase